Physician profile
Conor Patrick Dolehide
NPI 1992098735
$9,600.67
in general payments reported to CMS, 2019-2025
27 companies · $4,521 in 2025
The $4,521 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $61.62 · 2021: $24.38 · 2022: $409 · 2023: $1,909 · 2024: $2,528 · 2025: $4,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,669 · Consulting Fee: $2,100 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,668.58 |
| Consulting Fee | $2,100.00 |
| Education | $188.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,668.25 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,205.74 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $839.01 | 2021-2025 | Rinvoq, Skyrizi |
| Merz North America, INC. | $744.21 | 2023-2025 | Xeomin |
| Revance Therapeutics, INC. | $725.52 | 2024-2025 | Daxxify |
| Pfizer INC. | $606.04 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $517.99 | 2020-2025 | |
| Genzyme Corporation | $388.05 | 2023-2025 | |
| Dermavant Sciences, INC. | $332.11 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $309.34 | 2022-2024 | Dupixent |
| Genentech USA, INC. | $220.59 | 2022-2025 | Xolair |
| Smith+Nephew, INC. | $173.63 | 2023-2025 | Grafix, Grafix Pl |
| Arcutis Biotherapeutics, INC. | $165.95 | 2024-2025 | Zoryve |
| Organogenesis INC. | $133.09 | 2023-2025 | Puraply, Simplimax, Novachor |
| Organon LLC | $93.74 | 2025 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $79.26 | 2022 | |
| Galderma Laboratories, L.P. | $71.91 | 2024-2025 | Aklief |
| Dermira, INC. | $64.57 | 2019 | |
| Lilly USA, LLC | $49.66 | 2023-2025 | Ebglyss, Taltz |
| Biowound Solutions, INC. | $47.55 | 2025 | Bio-Connekt |
| Biofrontera INC. | $42.66 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dusa Pharmaceuticals, INC. | $27.78 | 2019 | |
| Ucb, INC. | $26.10 | 2025 | Bimzelx |
| Paratek Pharmaceuticals, INC. | $23.81 | 2025 | Nuzyra |
| Convatec INC. | $20.94 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.44 | 2019 | |
| Sensus Healthcare, INC. | $5.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conor Dolehide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.